Degree in Biochemistry from University of Minho, Portugal (2015). Master degree in Health Sciences from the University of Minho, Portugal (2017). Attends the PhD in Health Sciences in University of Minho since 2018, in the oncobiology field. Published 4 articles in journals, one of them as first co-author. Has 1 book section and has received 1 award in an international congress at Brazil (2019). The main research interests are: molecular targeted therapies in oncology and mechanisms of resistance, specifically, receptor tyrosine kinases (RTKs) as therapeutic targets and Raf Kinase Inhibitor Protein (RKIP), namely, its biologic functions, and its potential use as theranostic marker and also as therapeutic target in different solid tumors. Special interest in HPV-related cancers.
Degree in Biochemistry from University of Minho, Portugal (2015). Master degree in Health Sciences from the University of Minho, Portugal (2017). Attends the PhD in Health Sciences in University of Minho since 2018, in the oncobiology field. Published 4 articles in journals, one of them as first co-author. Has 1 book section and has received 1 award in an international congress at Brazil (2019). The main research interests are: molecular targeted therapies in oncology and mechanisms of resistance, specifically, receptor tyrosine kinases (RTKs) as therapeutic targets and Raf Kinase Inhibitor Protein (RKIP), namely, its biologic functions, and its potential use as theranostic marker and also as therapeutic target in different solid tumors. Special interest in HPV-related cancers.
Diana Cardoso-Carneiro, Ana Raquel-Cunha, Joana Pinheiro, Maria Gabriela-Freitas, Patríca Fontão, Rui M. Reis, Olga Martinho. Chapter 20, In “Prognostic and Therapeutic Applications of RKIP in Cancer”, Bonavida B. & Baritaki S., Elsevier. 2020
Vera Miranda-Gonçalves*, Diana Cardoso-Carneiro*, Inês Valbom, Fernanda Cury, Viviane Aline, Sara Granja, Fátima Baltazar, Rui M. Reis, Olga Martinho. Understanding the cellular metabolic reprogramming associated with bevacizumab therapy in glioblastoma. Oncotarget 2017, (IF=5.168). (*Co-authorship)
Diana Cardoso-Carneiro, Patrícia Cunha, Rosete Nogueira, Ana Raquel-Cunha, Ana Carolina Peters, André L. Carvalho, Rui M. Reis, Olga Martinho. “RKIP protein as a potential prognostic, aggressiveness and therapy response biomarker in HNSCC”. VII International Symposium on Translational Oncology, Barretos, Brazil, 13-14 September 2019 – Winner Poster.
EACR 2022 – EACR Meeting Bursary Award
Raf kinase inhibitor protein (RKIP), was first described as an inhibitor of MAPK pathway, which accounts for its current name. However, subsequent studies have shown that…
Phone: +351 253 604 967
Fax: +351 253 604 809
Email: icvs.sec@med.uminho.pt
Life and Health Sciences
Research Institute (ICVS)
School of Medicine,
University of Minho,
Campus de Gualtar
4710-057 Braga
Portugal
Copyright ©2022 ICVS. All Rights Reserved
Copyright ©2022 ICVS. All Rights Reserved
Life and Health Sciences
Research Institute (ICVS)
School of Medicine,
University of Minho,
Campus de Gualtar
4710-057 Braga
Portugal
Copyright ©2022 ICVS. All Rights Reserved
Life and Health Sciences
Research Institute (ICVS)
School of Medicine,
University of Minho,
Campus de Gualtar
4710-057 Braga
Portugal
